Loading
Envisagenics
Envisagenics is an AI-driven biotechnology company founded in 2014, focusing on the discovery and development of novel RNA splicing therapeutics for oncology and neurodegenerative diseases. Headquartered in Long Island City, New York, the company was co-founded by Dr. Maria Luisa Pineda and Dr. Martin Akerman, with roots in Cold Spring Harbor Laboratory. The company's core technology, SpliceCore®, is a cloud-based bioinformatics tool that utilizes machine learning and high-performance computing to analyze RNA splicing errors. This platform enhances drug target discovery, making it significantly more effective than traditional methods. Envisagenics collaborates with major biopharma companies, including Bristol-Myers Squibb and Biogen, to advance RNA splicing research and develop innovative therapeutic solutions. With a commitment to improving the lives of over 30 million patients affected by genetic diseases and cancer, Envisagenics emphasizes collaboration and patient-driven innovation in its mission.
Funding
Every round, secondary, debt facility or acquisition involving Envisagenics that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
$2M